AIM
CTKB icon

Aigen Investment Management’s Cytek Biosciences CTKB Stock Holding History

Aigen Investment Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.1K Buy
+14,029
New +$59.9K 0.02% 499
2025
Q3 		– Sell
-14,730
Closed -$50.1K – 851
2025
Q2 		$50.1K Buy
+14,730
New +$49.1K 0.01% 745
2023
Q1 		– Sell
-14,102
Closed -$144K – 661
2022
Q4 		$144K Buy
+14,102
New +$190K 0.02% 480

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Aigen Investment Management's CTKB Position: Q2 2026 in Review

Aigen Investment Management opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 14,029 shares worth $62.1K. The stake represents 0.02% of the portfolio and ranks #499 among its holdings. This is a return to the name: Aigen Investment Management previously reported a position in CTKB as recently as Q2 2025.

Aigen Investment Management first reported a position in CTKB in Q4 2022 and has held it in 3 quarters since. The position peaked at $144K in Q4 2022. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Aigen Investment Management held 14,029 shares of Cytek Biosciences worth $62.1K as of Q2 2026.
  • Cytek Biosciences was a new Aigen Investment Management position in Q2 2026.
  • Cytek Biosciences made up 0.02% of Aigen Investment Management's portfolio in Q2 2026, its #499 holding.
  • Aigen Investment Management first reported a position in Cytek Biosciences in Q4 2022 and has held it in 3 quarters since.
  • Aigen Investment Management's Cytek Biosciences position peaked at $144K in Q4 2022.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.